AstraZeneca PLC (AZN) EV/Assets Ratio: 2.73x
Is AstraZeneca PLC’s EV/Assets ratio high or low?
AstraZeneca PLC's EV/Assets ratio of 2.73x is 14% above its 5-year average of 2.40x, near the high end of its 5-year range (1.73x–3.07x).
As of Friday, June 12, 2026. 3.63% above its 12-month average of 2.63x.
AZN EV/Assets Ratio Chart
AZN Average EV/Assets Ratio Chart
AZN Current vs Average EV/Assets Ratio Chart
AZN EV/Assets Ratio Metrics
EV/ASSETS RATIO
2.73x
EV/ASSETS RATIO AVG TTM
2.63x
EV/ASSETS RATIO AVG 3Y
2.50x
EV/ASSETS RATIO AVG 5Y
2.40x
EV/ASSETS RATIO AVG 10Y
2.15x
EV/ASSETS RATIO AVG 15Y
1.90x
EV/ASSETS RATIO AVG 20Y
1.86x
CURRENT VS TTM AVG
+3.63%
CURRENT VS 3Y AVG
+9.39%
CURRENT VS 5Y AVG
+13.91%
CURRENT VS 10Y AVG
+26.82%
CURRENT VS 15Y AVG
+43.39%
CURRENT VS 20Y AVG
+46.83%
AZN Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 2.73x | 2.63x | 2.50x | 2.40x |
| Merck & Co., Inc. (MRK) | $298.29B | 2.66x | 2.21x | 2.57x | 2.53x |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 1.34x | 1.11x | 1.57x | 1.80x |
| Amgen Inc. (AMGN) | $191.09B | 2.57x | 2.46x | 2.27x | 2.38x |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 1.92x | 2.16x | 2.33x | 2.57x |
| AbbVie Inc. (ABBV) | $397.12B | 3.39x | 3.28x | 2.82x | 2.56x |
| Gilead Sciences, Inc. (GILD) | $156.28B | 3.06x | 3.05x | 2.44x | 2.15x |
| Abbott Laboratories (ABT) | $156.15B | 1.66x | 2.50x | 2.67x | 2.75x |
| Pfizer Inc. (PFE) | $149.18B | 1.02x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 7.29x | 8.87x | 9.09x | 8.50x |
AstraZeneca PLC EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EV/Assets Ratio FAQ
- What is the EV/Assets ratio for AstraZeneca PLC (AZN)?
- The EV/Assets ratio for AZN stock is 2.73x.
- Is AstraZeneca PLC's EV/Assets ratio high or low?
- AstraZeneca PLC's EV/Assets ratio of 2.73x is 14% above its 5-year average of 2.40x, near the high end of its 5-year range (1.73x–3.07x).
- What is the TTM average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The TTM average EV/Assets ratio for AZN stock is 2.63x.
- What is the 3Y average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The 3Y average EV/Assets ratio for AZN stock is 2.50x.
- What is the 5Y average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The 5Y average EV/Assets ratio for AZN stock is 2.40x.
- What is the 10Y average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The 10Y average EV/Assets ratio for AZN stock is 2.15x.
- What is the 15Y average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The 15Y average EV/Assets ratio for AZN stock is 1.90x.
- What is the 20Y average EV/Assets ratio for AstraZeneca PLC (AZN)?
- The 20Y average EV/Assets ratio for AZN stock is 1.86x.
AstraZeneca PLC EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-11 | 2.73x |
| 2026-06-10 | 2.68x |
| 2026-06-09 | 2.74x |
| 2026-06-08 | 2.72x |
| 2026-06-05 | 2.78x |
| 2026-06-04 | 2.72x |
| 2026-06-03 | 2.64x |
| 2026-06-02 | 2.66x |
| 2026-06-01 | 2.69x |
| 2026-05-29 | 2.77x |
| 2026-05-28 | 2.77x |
| 2026-05-27 | 2.77x |
| 2026-05-26 | 2.79x |
| 2026-05-22 | 2.79x |
| 2026-05-21 | 2.83x |
| 2026-05-20 | 2.80x |
| 2026-05-19 | 2.76x |
| 2026-05-18 | 2.75x |
| 2026-05-15 | 2.72x |
| 2026-05-14 | 2.76x |
| 2026-05-13 | 2.80x |
| 2026-05-12 | 2.76x |
| 2026-05-11 | 2.72x |
| 2026-05-08 | 2.73x |
| 2026-05-07 | 2.73x |
| 2026-05-06 | 2.76x |
| 2026-05-05 | 2.71x |
| 2026-05-04 | 2.74x |
| 2026-05-01 | 2.76x |
| 2026-04-30 | 2.80x |
| 2026-04-29 | 2.77x |
| 2026-04-28 | 2.77x |
| 2026-04-27 | 2.78x |
| 2026-04-24 | 2.81x |
| 2026-04-23 | 2.84x |
| 2026-04-22 | 2.88x |
| 2026-04-21 | 2.89x |
| 2026-04-20 | 2.96x |
| 2026-04-17 | 3.01x |
| 2026-04-16 | 2.96x |
| 2026-04-15 | 2.97x |
| 2026-04-14 | 3.01x |
| 2026-04-13 | 2.98x |
| 2026-04-10 | 3.00x |
| 2026-04-09 | 3.02x |
| 2026-04-08 | 3.01x |
| 2026-04-07 | 2.96x |
| 2026-04-06 | 2.99x |
| 2026-04-02 | 3.00x |
| 2026-04-01 | 2.96x |
| 2026-03-31 | 2.91x |
| 2026-03-30 | 2.87x |
| 2026-03-27 | 2.79x |
| 2026-03-26 | 2.72x |
| 2026-03-25 | 2.77x |
| 2026-03-24 | 2.75x |
| 2026-03-23 | 2.73x |
| 2026-03-20 | 2.72x |
| 2026-03-19 | 2.80x |
| 2026-03-18 | 2.79x |
| 2026-03-17 | 2.83x |
| 2026-03-16 | 2.84x |
| 2026-03-13 | 2.81x |
| 2026-03-12 | 2.85x |
| 2026-03-11 | 2.86x |
| 2026-03-10 | 2.88x |
| 2026-03-09 | 2.88x |
| 2026-03-06 | 2.87x |
| 2026-03-05 | 2.91x |
| 2026-03-04 | 2.97x |
| 2026-03-03 | 2.97x |
| 2026-03-02 | 3.00x |
| 2026-02-27 | 3.06x |
| 2026-02-26 | 3.00x |
| 2026-02-25 | 3.03x |
| 2026-02-24 | 3.04x |
| 2026-02-23 | 3.01x |
| 2026-02-20 | 3.00x |
| 2026-02-19 | 3.06x |
| 2026-02-18 | 3.06x |
| 2026-02-17 | 3.07x |
| 2026-02-13 | 3.02x |
| 2026-02-12 | 3.00x |
| 2026-02-11 | 3.01x |
| 2026-02-10 | 2.85x |
| 2026-02-09 | 2.78x |
| 2026-02-06 | 2.85x |
| 2026-02-05 | 2.77x |
| 2026-02-04 | 2.77x |
| 2026-02-03 | 2.73x |
| 2026-02-02 | 2.78x |
| 2026-01-30 | 2.77x |
| 2026-01-29 | 2.71x |
| 2026-01-28 | 2.78x |
| 2026-01-27 | 2.78x |
| 2026-01-26 | 2.66x |
| 2026-01-23 | 2.64x |
| 2026-01-22 | 2.66x |
| 2026-01-21 | 2.60x |
| 2026-01-20 | 2.71x |
| 2026-01-16 | 2.82x |
| 2026-01-15 | 2.79x |
| 2026-01-14 | 2.81x |
| 2026-01-13 | 2.79x |
| 2026-01-12 | 2.74x |
| 2026-01-09 | 2.82x |
| 2026-01-08 | 2.79x |
| 2026-01-07 | 2.82x |
| 2026-01-06 | 2.81x |
| 2026-01-05 | 2.66x |
| 2026-01-02 | 2.71x |
| 2025-12-31 | 2.61x |
| 2025-12-30 | 2.68x |
| 2025-12-29 | 2.77x |
| 2025-12-26 | 2.69x |
| 2025-12-24 | 2.76x |
| 2025-12-23 | 2.71x |
| 2025-12-22 | 2.68x |
| 2025-12-19 | 2.69x |
| 2025-12-18 | 2.68x |
| 2025-12-17 | 2.73x |
| 2025-12-16 | 2.71x |
| 2025-12-15 | 2.72x |
| 2025-12-12 | 2.66x |
| 2025-12-11 | 2.68x |
| 2025-12-10 | 2.70x |
| 2025-12-09 | 2.66x |
| 2025-12-08 | 2.68x |
| 2025-12-05 | 2.66x |
| 2025-12-04 | 2.67x |
| 2025-12-03 | 2.71x |
| 2025-12-02 | 2.66x |
| 2025-12-01 | 2.67x |
| 2025-11-28 | 2.72x |
| 2025-11-26 | 2.79x |
| 2025-11-25 | 2.77x |
| 2025-11-24 | 2.71x |
| 2025-11-21 | 2.70x |
| 2025-11-20 | 2.64x |
| 2025-11-19 | 2.67x |
| 2025-11-18 | 2.60x |
| 2025-11-17 | 2.60x |
| 2025-11-14 | 2.60x |
| 2025-11-13 | 2.64x |
| 2025-11-12 | 2.61x |
| 2025-11-11 | 2.60x |
| 2025-11-10 | 2.60x |
| 2025-11-07 | 2.48x |
| 2025-11-06 | 2.52x |
| 2025-11-05 | 2.48x |
| 2025-11-04 | 2.52x |
| 2025-11-03 | 2.47x |
| 2025-10-31 | 2.51x |
| 2025-10-30 | 2.51x |
| 2025-10-29 | 2.50x |
| 2025-10-28 | 2.53x |
| 2025-10-27 | 2.50x |
| 2025-10-24 | 2.50x |
| 2025-10-23 | 2.56x |
| 2025-10-22 | 2.54x |
| 2025-10-21 | 2.56x |
| 2025-10-20 | 2.54x |
| 2025-10-17 | 2.60x |
| 2025-10-16 | 2.57x |
| 2025-10-15 | 2.56x |
| 2025-10-14 | 2.57x |
| 2025-10-13 | 2.57x |
| 2025-10-10 | 2.58x |
| 2025-10-09 | 2.58x |
| 2025-10-08 | 2.62x |
| 2025-10-07 | 2.59x |
| 2025-10-06 | 2.62x |
| 2025-10-03 | 2.59x |
| 2025-10-02 | 2.51x |
| 2025-10-01 | 2.48x |
| 2025-09-30 | 2.30x |
| 2025-09-29 | 2.26x |
| 2025-09-26 | 2.26x |
| 2025-09-25 | 2.31x |
| 2025-09-24 | 2.30x |
| 2025-09-23 | 2.32x |
| 2025-09-22 | 2.40x |
| 2025-09-19 | 2.37x |
| 2025-09-18 | 2.36x |
| 2025-09-17 | 2.39x |
| 2025-09-16 | 2.35x |
| 2025-09-15 | 2.37x |
| 2025-09-12 | 2.44x |
| 2025-09-11 | 2.48x |
| 2025-09-10 | 2.45x |
| 2025-09-09 | 2.46x |
| 2025-09-08 | 2.49x |
| 2025-09-05 | 2.51x |
| 2025-09-04 | 2.48x |
| 2025-09-03 | 2.48x |
| 2025-09-02 | 2.46x |
| 2025-08-29 | 2.46x |
| 2025-08-28 | 2.42x |
| 2025-08-27 | 2.46x |
| 2025-08-26 | 2.45x |
| 2025-08-25 | 2.49x |
| 2025-08-22 | 2.41x |
| 2025-08-21 | 2.46x |
| 2025-08-20 | 2.42x |
| 2025-08-19 | 2.44x |
| 2025-08-18 | 2.45x |
| 2025-08-15 | 2.39x |
| 2025-08-14 | 2.39x |
| 2025-08-13 | 2.37x |
| 2025-08-12 | 2.29x |
| 2025-08-11 | 2.26x |
| 2025-08-08 | 2.20x |
| 2025-08-07 | 2.27x |
| 2025-08-06 | 2.29x |
| 2025-08-05 | 2.31x |
| 2025-08-04 | 2.31x |
| 2025-08-01 | 2.27x |
| 2025-07-31 | 2.27x |
| 2025-07-30 | 2.39x |
| 2025-07-29 | 2.32x |
| 2025-07-28 | 2.37x |
| 2025-07-25 | 2.38x |
| 2025-07-24 | 2.41x |
| 2025-07-23 | 2.41x |
| 2025-07-22 | 2.33x |
| 2025-07-21 | 2.30x |
| 2025-07-18 | 2.27x |
| 2025-07-17 | 2.28x |
| 2025-07-16 | 2.34x |
| 2025-07-15 | 2.31x |
| 2025-07-14 | 2.35x |
| 2025-07-11 | 2.31x |
| 2025-07-10 | 2.36x |
| 2025-07-09 | 2.33x |
| 2025-07-08 | 2.31x |
| 2025-07-07 | 2.34x |
| 2025-07-03 | 2.32x |
| 2025-07-02 | 2.36x |
| 2025-07-01 | 2.30x |
| 2025-06-30 | 2.30x |
| 2025-06-27 | 2.28x |
| 2025-06-26 | 2.31x |
| 2025-06-25 | 2.40x |
| 2025-06-24 | 2.32x |
| 2025-06-23 | 2.34x |
| 2025-06-20 | 2.30x |
| 2025-06-18 | 2.36x |
| 2025-06-17 | 2.32x |
| 2025-06-16 | 2.43x |
| 2025-06-13 | 2.42x |
| 2025-06-12 | 2.45x |
| 2025-06-11 | 2.43x |
| 2025-06-10 | 2.40x |
| 2025-06-09 | 2.40x |
| 2025-06-06 | 2.37x |
| 2025-06-05 | 2.35x |
| 2025-06-04 | 2.39x |
| 2025-06-03 | 2.34x |
| 2025-06-02 | 2.34x |
| 2025-05-30 | 2.33x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot